# High density lipoproteins, disease severity and clinical outcomes in patients with idiopathic pulmonary fibrosis

## TL;DR

This study found that higher levels of a protein called ApoA1 in the blood are linked to fewer hospitalizations in patients with a lung disease called idiopathic pulmonary fibrosis.

## Contribution

The study identifies ApoA1 as a potential biomarker for predicting respiratory hospitalization risk in idiopathic pulmonary fibrosis patients.

## Key findings

- Higher ApoA1 levels were associated with lower risk of respiratory hospitalization in IPF patients.
- The association between ApoA1 and hospitalization remained significant after adjusting for demographic and clinical variables.
- PON-1 and HDL-C levels were not significantly linked to mortality or hospitalization outcomes.

## Abstract

Dysregulation of lipid metabolism is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). We assessed associations between circulating levels of high-density lipoprotein-cholesterol (HDL-C) and its components apolipoprotein A-1 (ApoA1) and paraoxonase-1 (PON-1) and disease severity and outcomes in patients with IPF.

The cohort comprised 284 patients enrolled in the IPF-PRO Registry. We analyzed associations between HDL-C, ApoA1 and PON-1 levels at enrollment and measures of disease severity at enrollment (using linear regression) and outcomes during follow-up (using Cox models). Models were adjusted for demographic and clinical variables, including cardiovascular disease and statin use, assessed at enrollment.

In unadjusted models, higher ApoA1 and lower PON-1 were associated with higher FVC % predicted at enrollment. Median follow-up was 40 months. In unadjusted models, higher ApoA1 at enrollment was associated with lower risks of all-cause mortality (hazard ratio [HR] 0.32 [95% CI: 0.16, 0.64] per unit higher log2 ApoA1) and respiratory hospitalization (HR 0.25 [0.11, 0.57] per unit higher log2 ApoA1). In analyses adjusted for demographic and clinical variables, the association with respiratory hospitalization remained significant (HR 0.30 [95% CI: 0.10, 0.88; p = 0.029]), but the association with all-cause mortality was no longer significant (HR 0.44 [95% CI: 0.18, 1.08; p = 0.074]). Levels of PON-1 or HDL-C were not associated with all-cause mortality or respiratory hospitalization.

In a real-world cohort of patients with IPF, a higher circulating level of ApoA1 was associated with a lower risk of respiratory hospitalization. ApoA1 is a potential prognostic biomarker in patients with IPF.